Undervalued Small Caps In United States With Insider Buying

In This Article:

The United States market has shown robust performance recently, climbing 1.5% in the last week and an impressive 33% over the past year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying small-cap stocks that are potentially undervalued and exhibit insider buying can be a strategic approach for investors seeking opportunities aligned with current market trends.

Top 10 Undervalued Small Caps With Insider Buying In The United States

Name

PE

PS

Discount to Fair Value

Value Rating

Hanover Bancorp

9.4x

2.2x

48.05%

★★★★★☆

Columbus McKinnon

22.0x

1.0x

40.08%

★★★★★☆

Citizens & Northern

13.0x

2.9x

42.48%

★★★★☆☆

HighPeak Energy

12.1x

1.5x

35.42%

★★★★☆☆

German American Bancorp

14.2x

4.8x

46.56%

★★★☆☆☆

Community West Bancshares

18.7x

2.9x

42.25%

★★★☆☆☆

Orion Group Holdings

NA

0.3x

-102.79%

★★★☆☆☆

Sabre

NA

0.4x

-33.51%

★★★☆☆☆

Delek US Holdings

NA

0.1x

-752.06%

★★★☆☆☆

Industrial Logistics Properties Trust

NA

0.7x

-217.32%

★★★☆☆☆

Click here to see the full list of 52 stocks from our Undervalued US Small Caps With Insider Buying screener.

Let's take a closer look at a couple of our picks from the screened companies.

Phibro Animal Health

Simply Wall St Value Rating: ★★★★★☆

Overview: Phibro Animal Health is a company that specializes in animal health products, mineral nutrition, and performance products, with a market cap of approximately $0.58 billion.

Operations: The company generates revenue primarily from Animal Health, followed by Mineral Nutrition and Performance Products segments. Over the years, the gross profit margin has shown a trend of gradual increase, reaching 30.82% in recent periods. Operating expenses have consistently been a significant component of costs, with general and administrative expenses forming a substantial part.

PE: 407.2x

Phibro Animal Health, a smaller player in the U.S. market, shows insider confidence with recent share purchases. Despite a challenging financial position, relying heavily on external borrowing, they project net sales of US$1.04 billion to US$1.09 billion for fiscal 2025. Recent earnings reveal mixed results: quarterly sales rose to US$273 million from last year, yet net income dropped significantly. With anticipated growth in their Animal Health segment and ongoing dividend payments, Phibro's future holds potential amidst current volatility.

NasdaqGM:PAHC Share price vs Value as at Oct 2024
NasdaqGM:PAHC Share price vs Value as at Oct 2024

Reservoir Media

Simply Wall St Value Rating: ★★★☆☆☆